IL17A and rheumatoid arthritis: Therefore, it has been suggested that the anti-IL-17A antibody is effective against PsA, causing osteogenesis of the joint (McInnes et al, 2015; Mease et al, 2017), but not rheumatoid arthritis caused by bone and cartilage destruction (Genovese et al, 2013).